A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
Human medicines European public assessment report (EPAR): Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.), beclometasone / formoterol / glycopyrronium bromide, Pulmonary Disease, Chronic Obstructive, Date of authorisation: 23/04/2018, Revision: 1, Status: Authorised
2019
Case Medical Research
Preserved Fulltext
